{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:44:38Z","timestamp":1777877078637,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The recent availability of infliximab subcutaneous biosimilar in Europe represents a significant advancement in therapeutic delivery. Real-world data regarding the new formulation are still limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To describe subcutaneous infliximab (scIFX) use in immune-mediated inflammatory diseases (IMIDs), evaluating clinical effectiveness, treatment persistence, and factors influencing drug retention rates (DRRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Adult patients with IMIDs treated with scIFX either de novo or after switching from intravenous infliximab (ivIFX) were included. Disease activity was assessed using standard indices, and persistence was evaluated through 18-month DRRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 201 patients were included (66.7% women): 68 with psoriatic arthritis (33.8%), 66 axial spondyloarthritis (32.8%), 18 rheumatoid arthritis (9.0%), 18 Beh\u00e7et\u2019s disease (9.0%), 16 juvenile idiopathic arthritis (8.0%), 10 Takayasu arteritis (5.0%), and 5 other IMIDs (2.5%). Median treatment duration was 14\u2009months (interquartile range 13.0). Ninety-five patients (47.3%) switched from ivIFX, while 106 initiated scIFX de novo, of whom 74 (78.3%) received induction. Median disease activity grades improved from baseline through 24\u2009months (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Fifty-five subjects (27.4%) discontinued scIFX. DRRs were 88.5%, 76.9%, and 68.3% at 6, 12, and 18\u2009months, respectively. DRRs were higher in switchers versus de novo initiators (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.038), also controlling for baseline activity and loading protocol (hazard ratio\u2009=\u20090.25 [95% confidence interval: 0.075\u20130.848],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.026). De novo patients without induction had lower DRRs (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.033) than those receiving induction, whereas line of biologic therapy (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.066) and body mass index (BMI;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.445) had no effect on scIFX DRRs. Adverse events occurred in 21 patients (10.4%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ScIFX appears effective across IMIDs, with sustained retention over time. Prior ivIFX exposure and use of induction protocols are associated with improved persistence, while treatment line and BMI appear not to influence outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x261442376","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T01:41:31Z","timestamp":1777254091000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["A snapshot of subcutaneous infliximab uses in inflammatory rheumatic diseases: a multicentric Italian study"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6658-1037","authenticated-orcid":false,"given":"Stefano","family":"Gentileschi","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-8343","authenticated-orcid":false,"given":"Carla","family":"Gaggiano","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Department of Medical Sciences, Surgery and Neurosciences, Siena University Hospital, University of Siena, Viale Mario Bracci 16, Siena 53100, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Placido","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Terribili","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7710-5025","authenticated-orcid":false,"given":"Laura","family":"Cometi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Dipietrangelo","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Cozzi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Padoan","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Bixio","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Parisi","sequence":"additional","affiliation":[{"name":"SC Reumatologia, AOU Citt\u00e0 della Salute e della Scienza, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Chiara","family":"Ditto","sequence":"additional","affiliation":[{"name":"SC Reumatologia, AOU Citt\u00e0 della Salute e della Scienza, Torino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Lepri","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Fabiani","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, Department of Medical Sciences, Surgery and Neuroscience, University of Siena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7352-1275","authenticated-orcid":false,"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":false,"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Guiducci","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.12.009"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-1324-x"},{"key":"e_1_3_4_4_2","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Remsima: EPAR\u2014product information. European Medicines Agency https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima (2025 accessed 26 May 2025)."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa580"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102849"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae015"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2023.2286191"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24782"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02487-x"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1858803"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5233"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5205"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1583401"},{"issue":"1","key":"e_1_3_4_16_2","first-page":"250","article-title":"Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis","volume":"25","author":"Shuai ZQ","year":"2021","unstructured":"Shuai ZQ, Zhang CX, Shuai ZW, et al. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2021; 25(1): 250\u2013262.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02830"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1817379"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001835"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-019-0645-4"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-018-4159-1"},{"key":"e_1_3_4_22_2","article-title":"A prospective observational study on the efficacy and safety of infliximab-biosimilar (CT-P13) in patients with Takayasu arteritis (TAKASIM)","volume":"8","author":"Campochiaro C","year":"2021","unstructured":"Campochiaro C, Tomelleri A, Sartorelli S, et al. A prospective observational study on the efficacy and safety of infliximab-biosimilar (CT-P13) in patients with Takayasu arteritis (TAKASIM). Front Med (Lausanne) 2021; 8: 723506.","journal-title":"Front Med (Lausanne)"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.20344\/amp.19734"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2022.05.19"},{"issue":"6","key":"e_1_3_4_25_2","first-page":"767","article-title":"Vascular complications of Beh\u00e7et disease","volume":"112","author":"Mezalek ZT","year":"2022","unstructured":"Mezalek ZT, Aoun N, Fedoukh T, et al. Vascular complications of Beh\u00e7et disease. Minerva Med 2022; 112(6): 767\u2013778.","journal-title":"Minerva Med"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15754"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-025-01206-2"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02993-9"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roab012"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/r4gnxm"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01340-1"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103357"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.1094"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261442376","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X261442376","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X261442376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:40:44Z","timestamp":1777588844000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X261442376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"alternative-id":["10.1177\/1759720X261442376"],"URL":"https:\/\/doi.org\/10.1177\/1759720x261442376","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"1759720X261442376"}}